Definitive Contract HHSN261201600028C
Award Date
9/19/16
Potential Completion Date
9/18/20
Potential Value
$1.5M
Federal Agency
National Cancer Institute
Awardee
Qrono, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Pittsburgh, PA 15213, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $223,412 Small Business Innovation Research (SBIR) Program Phase I contract to Qrono, Inc. for the development of a "Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer." This Firm Fixed Price contract with a completion date of September 30, 2015 aims to advance an innovative approach to treating head and neck cancer by reformulating a...
This federal contract award was made by the Food and Drug Administration (FDA), a civilian agency, to Qrono, Inc., a for-profit company specializing in medical and scientific research and development. The $694,584.58 cost-plus-fixed-fee contract, titled "Computational Drug Delivery: Leveraging Predictive Models to Develop Bioequivalent Generic Long-Acting Injections," is focused on developing innovative drug delivery systems and immunotherapy approaches. The contract has an ultimate...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $597,598 firm fixed price definitive contract to Qrono Inc., located in Carson, Pennsylvania, to conduct research related to APC Specific MTOP Inhibition Potentiates Immune Response to IIV in Elderly Recipients. The contract is set aside as a total small business and will run from January 10, 2022 through January 9, 2024. Qrono Inc. will serve as the prime...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
This is a federal contract award from the U.S. Army Medical Command (MEDCOM) to Qrono, Inc., a small business. The contract is a Small Business Innovation Research (SBIR) Phase I award valued at $149,927.50 with a firm fixed price. The contract was awarded on September 15, 2015 and has an ultimate completion date of July 31, 2017. The contract is focused on medical and scientific research and development, with Qrono, Inc. specializing in innovative drug delivery systems and immunotherapy...
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Quantum Mark, LLC, a woman-owned small business. The $749,995.54 cost-plus-fixed-fee contract was awarded under the Small Business Innovation Research (SBIR) Phase II program to develop software systems to facilitate the use of electronic data records in the collection of population-based cancer surveillance data. The contract has a period of performance through June 29, 2012 and was set aside for...
<p>This is a cost-plus-fixed-fee SBIR Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to LP Therapeutics, Inc. for the development of novel therapeutic agents targeting cancer stem cells. The contract has a total ceiling value of $1,489,000.12 and a period of performance ending on March 18, 2019. The contract was set aside for small businesses. No information is provided about major subcontractors.</p>
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of "functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles" for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Qana Therapeutics Inc. The $354,672 Firm Fixed Price contract is for the development of therapeutic technologies targeting ferroptosis inducers for the treatment of adrenocortical carcinoma, a rare cancer type. The contract is part of the NCI's SBIR Innovative Concept Award Program, which seeks innovative and potentially transformative technologies for the...